Results 141 to 150 of about 1,179,909 (205)

Double-Edge Effects of Leucine on Cancer Cells. [PDF]

Biomolecules
Akbay B, Omarova Z, Trofimov A, Sailike B, Karapina O, Molnár F, Tokay T.   +6 more
europepmc   +1 more source

A comprehensive review on pain: Model, target, therapy, and prospect (Review). [PDF]

Int J Mol Med
Chang C, Wu X, Liu K, Wang L, Adu M, Lin Q, Huang H, Ma Q, Wei R, Wang X, Liu W.   +10 more
europepmc   +1 more source

Integrated epidemiological and molecular data inform the relationship between precancer and cancer states of esophageal adenocarcinoma. [PDF]

Nat Med
Zamani SA, Wu L, Black EL, Bartram A, Ng AWT, Secrier M, Perelman JD, Ustaoglu A, Ococks E, Jacobson D, Devonshire G, Grehan N, Nützinger B, Freeman A, Miremadi A, O'Donovan M, Frankell AM, Killcoyne S, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Coleman HG, Fitzgerald RC.   +20 more
europepmc   +1 more source

Instrumented Walkway Gait Analysis Predicts Fallers in Neurological Disorders: Identifying Digital Biomarkers for Balance Monitoring. [PDF]

Sensors (Basel)
You VS, Barnard LR, Botha H, Jackson LM, Bower JH, Klassen BT, Elder BD, Graff-Radford J, Howe CL, Ali F.   +9 more
europepmc   +1 more source

Effects of β-hydroxy-β-methylbutyrate on skeletal muscle loss in a mouse model of esophageal squamous cell carcinoma. [PDF]

Ann Transl Med
Yamamoto M, Koyanagi K, Nishi T, Kazuno A, Shoji Y, Ninomiya Y, Kanamori K, Tajima K, Nakashima R, Mori M.   +9 more
europepmc   +1 more source

Synergy of PET and MR imaging in the local and regional staging of bladder cancer. [PDF]

Ther Adv Urol
Xu MC, Sandberg ML, Childs DD, Cengiz TB, Walker CH, Rais-Bahrami S.   +5 more
europepmc   +1 more source

Metabolic, Inflammatory, and Molecular Impact of Cancer Cachexia on the Liver. [PDF]

Int J Mol Sci
Gonçalves DC, Gomes SP, Seelaender M.
europepmc   +1 more source

Phytochemistry, Bioavailability, and Molecular Mechanisms Underlying Multitarget Anticancer Activity of <i>Aloe vera</i>. [PDF]

Nutrients
Haroon N, Amjad A, Maaz M, Noman AM, Anees N, Muhammad Z, Shah M, Abdulmonem WA.   +7 more
europepmc   +1 more source

INHIBITION OF WALKER CARCINOMA 256 BY 6-AMINONICOTINAMIDE

Canadian Journal of Biochemistry and Physiology, 1957
The nicotinamide antagonist, 6-aminonicotinamide, was administered for 2 days prior to, and for 10 days following, the transplant of a rapidly growing Walker carcinoma 256. At a dose which did not produce pronounced loss of body weight (0.5 mg./kg.), a significant inhibition of the tumor was observed.
J D, McCOLL, W B, RICE, V W, ADAMKIEWICZ
openaire   +3 more sources